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Abstract:  Fibromyalgia  syndrome  (FS)  is  a  common  musculoskeletal  disorder  characterized  by  otherwise  unexplained  chronic 
widespread pain, a lowered pain threshold, high tender point counts, sleep disturbances, fatigue, headache, irritable bowel syndrome, 
morning stiffness, paraesthesias in the extremities, often psychological distress and depressed mood. Consequently, FS has a negative 
impact on working capacity, family life, social functioning and quality of life. Because of unknown etiology and not clearly understood 
pathogenesis, there is no standard therapy regime for FS. A variety of medical treatments, including antidepressants, opioids, analgesic 
or non-steroidal anti-inflammatory drugs, sedatives, muscle relaxants and antiepileptics, have been used to treat FS. Currently, no 
pharmacological treatment for FS is consistently successful. According to recent guidelines, the optimal treatment of FS requires a 
multidisciplinary approach with a combination of non-pharmacological and pharmacological treatment modalities. Spa therapy is a 
popular treatment for FS in many European countries, as well as in Japan and Israel. However, despite their long history and popularity 
spa treatments are still the subject of debate and their role in modern medicine is still not clear. The objective of this review is to 
summarize the currently available information on clinical effects and mechanism of action of spa therapy in FS. We also provide some 
suggestions for further development in this area.
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Introduction
Fibromyalgia syndrome (FS) is a chronic musculosk-
eletal pain disorder characterized by widespread pain 
and tenderness at marked sites of the body defined as 
tender points. It often is accompanied by other charac-
teristic symptoms as sleep disturbances, fatigue, head-
ache,  irritable  bowel  syndrome,  morning  stiffness, 
paraesthesia of the extremities, frequent psychologi-
cal distress, and depressed mood.1 The prevalence of 
FS in the general population is estimated as 1%–2%, 
and it affects mainly women, six times more com-
mon than men.2–5 As in other disabling conditions, 
FS  influences  working   capacity,  family life, social 
functioning, and quality of life (QoL).6 Furthermore, 
it has been demonstrated that the QoL of relatives of 
FS patients also is impaired.7 The   pathophysiologic 
mechanisms  underlying  FS  are  still  poorly  under-
stood  but  most  probably  include  complex  and 
  interrelated disturbances of the neurobiological stress 
system (ie, the hypothalamic-pituitary-adrenal [HPA] 
axis, sympathetic nervous system, and different brain 
neurotransmitters).8,9 These include reduced levels of 
biogenic amines, increased concentrations of excit-
atory  neurotransmitters,  including  substance  P  and 
dysregulation of the HPA axis. A unifying hypoth-
esis is that FS results from sensitization of the central 
  nervous system.1
Because of unknown etiology and unclear patho-
genesis, there are no standard therapy regime for FS. 
In recent years, at least three sets of guidelines have 
been developed by different medical organizations in 
an attempt to standardize the treatment of this con-
dition  (American  Pain  Society,  European  League 
Against  Rheumatism,  Association  of  the  Medical 
Society  of  Germany).10–12  Optimal  management  of 
FS includes a multidisciplinary approach with a com-
bination of non-pharmacological and pharmacologi-
cal treatment modalities tailored according to pain 
intensity, function, and associated features such as 
depression, fatigue, and sleep disturbance, decided 
through  discussion  with  the  patient.10–12  A  variety 
of  medical  treatments,  including  antidepressants 
(ie,   amitriptyline, duloxetine, fluoxetine, and moclo-
bemide), analgesics (ie, paracetamol and weak opi-
oids like tramadol), non-steroidal anti-inflammatory 
drugs  (NSAIDs),  sedatives,  muscle  relaxants,  and 
antiepileptics have been used to treat FS.10–12 Given 
the   complexity and chronicity of FS and the relatively 
poor response to pharmacological treatments, it is not 
  surprising that patients often resort to complementary 
or alternative therapies.13 Non-pharmaceutical treat-
ment modalities, including exercise, physical therapy, 
massage,  acupuncture,  homeopathy,  dietary,  osteo-
pathic  manipulation,  patient  education,  cognitive 
behavioral therapy and spa therapy were proposed 
from various authors.10–17 There is strong evidence that 
cognitive behavioral therapy (CBT) and exercises are 
effective in FS.10 Spa therapy comprises a broad spec-
trum of therapeutic modalities including hydrotherapy, 
balneotherapy, physiotherapy, mud-pack therapy, and 
exercise.18–20 This therapeutic approach has been suc-
cessfully used in many European countries, as well as 
in Japan and Israel for various illnesses. Nowadays, 
it still represents a popular treatment for many rheu-
matic diseases, such as FS, because of their chronic 
nature, problems related to the use of drugs that often 
have significant side effects, and the occasional lack 
of valid therapeutic strategies. Thousands of years 
of history and the abundance of spa resorts in many 
European countries have undoubtedly contributed to 
the popularity of these therapies.20
However,  despite  their  long  history  and  popu-
larity, spa treatments are still the subject of debate, 
and their role in modern medicine is still not clear.21 
We    summarize  the  currently  available  information 
on clinical effects and mechanism of action of spa 
  therapy in FS.
Randomized clinical Trials (RcTs)  
on spa Therapy in Fs
We conducted a search of the literature in May 2011. In 
an attempt to standardize the patient sample included, 
the search was conducted from 1990 (the date of pub-
lication of the ACR classification criteria for FS) to 
May  2011.5  Medline  was  searched  using  the  term 
“randomized clinical trial”, “spa therapy”, “mud” and 
“balneotherapy” in combination with FS. RCTs writ-
ten in languages other than English were excluded 
from the search. We identified eight articles that met 
our inclusion criteria reporting seven RCTs on spa 
therapy in FS, including a total number of patients of 
314 (Table 1). More than 90% of the participants in 
the studies were women. All studies were single blind 
with an “assessor” blind to the type of   treatment. In 
five studies, mineral baths were used: in one study 
bathing was combined with exercise   treatment, one Spa therapy and fibromyalgia
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study  evaluated  the  effect  of  spa  therapy  and  one 
studied the effect of mud-pack treatment.
Yurtkuran  et  al22  investigated  the  effect  of  the 
addition of balneotherapy to relaxation exercises in 
40 patients with FS. The study was conducted in a 
daily  living  environment  and  the  treatment  dura-
tion was 2 weeks. Patients taking part in the balneo-
therapy program bathed at 37 °C for 20 min a day, 
5 days per week followed by relaxation exercises. 
Patients in the control group received only relaxation 
exercises. Pain relief, as scored by Visual Analogue 
Scale (VAS), was achieved in both groups at the end 
of therapy and persisted for 6 weeks; however, sig-
nificant improvements in mean Pressure Algometric 
Scores (PAS) during follow-up were only observed in 
the balneotherapy group.
Buskila et al23 and Neumann et al24 reported in two 
different papers the beneficial effect of Dead Sea bal-
neotherapy on FS-related symptoms and QoL index 
in patients with FS. The authors enrolled 48 patients 
with FS, who were randomly assigned to treatment 
and control groups of 24 subjects each. The patients 
in the treatment group bathed for 20 min per day in 
a sulfur pool at 37 °C for 10 days, whereas the con-
trol group did not receive this treatment. All partici-
pants stayed in the Dead Sea area for 10 days and 
continued their regular medications for FS. Physical 
functioning,  assessed  by  the  Fibromyalgia  Impact 
Questionnaire  (FIQ),  and  FS-related  symptoms, 
assessed by VAS, Functional Disability Index (FDI), 
Health Assessment Questionnaire (HAQ), tenderness 
measurements (Tender Point Count [TPC] and dolo-
rimetry), and QoL index (Short Form-36 [SF36] and 
Arthritis Impact Measurement Scales [AIMS]) were 
recorded  at  baseline,  at  the  end  of  treatment,  and 
1 month and 3 months later. Physical functioning and 
tenderness improved moderately in both groups. With 
the exception of tenderness threshold, the improve-
ment was especially evident in the treatment group 
and even persisted beyond 3 months. Relief in the 
severity of FS-related symptoms (pain, fatigue, and 
stiffness) and reduced frequency of symptoms (head-
ache, sleep disturbances and subjective joint swell-
ing) were reported in both groups, but lasted longer in 
the treatment group. Significant improvement in most 
subscales of the SF36 was reported for both groups. 
Interestingly, the improvement in physical   components 
of the QoL index usually lasted 3 months, whereas 
improvement  in  measures  of  psychological  well-
being was of shorter duration. Improvements in the 
control group were explained by temporary changes 
in lifestyle combined with the relaxed atmosphere of 
the Dead Sea resort. In conclusion, the authors dem-
onstrated that staying in a Dead Sea spa, especially 
while receiving balneotherapy, improves FS-related 
symptoms and ameliorates some aspects of QoL, at 
least for 3 months.
Evcik et al25 also reported significant improvements 
lasting up to 6 months in patients treated with balneo-
therapy. In this study, 42 patients (with ages ranged 
between 30 and 55 years and without cardiovascular 
comorbidities)  with  FS  were  randomly  assigned  to 
two groups. One group (22 patients) bathed for 20 min 
at 36 °C once a day, five times per week for 3 con-
secutive weeks (total 15 sessions), and the other group 
(20  patients)  continued  their  regular  medications 
without balneotherapy. Patients were evaluated using 
TPC, VAS for pain, Beck’s   Depression Index (BDI), 
and FIQ at basal time, after therapy and 6 months later. 
The balneotherapy group showed statistically signifi-
cant improvements in TPC, VAS score, FIQ, and BDI 
values at the end of therapy; at 6 months, the improve-
ment in all parameters except BDI persisted.
A study by Donmez et al26 compared the effects 
of a stay at a spa center plus balneotherapy and the 
effects of regular care (control), recording significant 
improvements in major outcome measures, such as 
pain, TPC, and FIQ with respect to control. The pain 
and TPC results persisted for up to one month and 
the FIQ results for up to 6 months. However, they 
also could be attributed to the effects of the spa stay 
(not offered to controls, who continued their habitual 
medical treatment and/or daily exercises).
Ardiç et al27 investigated the clinical effects of bal-
neotherapy in the treatment of FS, considering serum 
levels of certain inflammatory markers, such as inter-
leukin-1 (IL-1), prostaglandin E2 (PGE2) and leukot-
riene B4 (LTB4). One group of patients (n = 22) bathed 
20 min per day for five days per week for three con-
secutive weeks, and the other group (n = 22) (control) 
continued with pharmacological treatment. A statis-
tically significant improvement in algometric score, 
VAS, BDI, TPC, and FIQ and a significant decrease 
of the mentioned inflammatory markers were only 
found in the balneotherapy group at the end of the 
treatment cycle.Spa therapy and fibromyalgia
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In  a  multicentric  single-blind  RCT  study, 
  Fioravanti et al28 assessed the effects of a combina-
tion of mud packs and thermal baths (with two types 
of mineral water) on patients with primary FS who 
responded poorly to pharmacological therapy. They 
also  analyzed  tolerance  to  mud  packs  because  no 
trial using this thermal treatment has been performed 
in FS. Eighty patients with primary FS were ran-
domly allocated to two groups: 40 underwent a cycle 
of 12 mud packs and thermal baths over a period of 
2 weeks, and 40 were enrolled as controls and con-
tinued their regular outpatient care routine. Because 
many other non-specific factors also may contribute 
to the effects observed after spa therapy, including 
changes in the environment, pleasant scenery, and the 
absence of work duties, to temper these factors, all 
patients lived near the spa, continued working, and 
did not modify their lifestyles. Another aspect that 
often amplifies the effects of spa therapy is its fre-
quent association with physio-kinesiotherapy. These 
treatments were excluded from the protocol if they 
had not yet begun and were not already   established. 
The following parameters were evaluated at base-
line,  after  thermal  treatment,  and  after  16  weeks: 
FIQ, TPC, VAS for “minor” symptoms, AIMS1, and 
HAQ. Controls were assessed at the same intervals. 
A  significant  improvement  in  all  parameters  was 
recorded after mud-pack therapy and after 16 weeks. 
The results were similar for the two types of mineral 
water.  Regarding  tolerance  mud  packs,  no  patient 
reported any exacerbation of symptoms, and the hot 
applications were well tolerated by all. No drop-outs 
occurred during spa therapy, and all patients com-
pleted the study.
Özkurt et al29 investigated the efficacy of balneo-
therapy in 50 women with FS randomly assigned to 
either the balneotherapy (25) or the control (25) group. 
The patients in the balneotherapy group had 2 thermo-
mineral water baths daily for 2 weeks in the Tuzla Spa 
Center. The patients in the control group continued to 
have their medical treatment and routine daily life. 
Outcome measures of the study were pain intensity 
(VAS score), FIQ, BDI, Patient’s and Investigator’s 
Global Assessment (PGA and IGA) scores, and SF36. 
Balneotherapy was found to be superior at the end of 
the cure period in terms of pain intensity, FIQ, BDI, 
PGA and IGA scores, and TPC as compared with 
the control group. The superiority of balneotherapy 
lasted up to the end of the 3rd month, except for the 
BDI score and the IGA scores.
Mechanism of Action of spa  
Therapy in Fs
The mechanisms by which immersion in mineral or 
thermal water or the application of mud alleviates 
chronic pain and the symptoms of FS are not com-
pletely known. The net benefit is probably the result of 
a combination of factors, among which, mechanical, 
thermal, and chemical effects are most prominent.18–20 
A distinction can be made between the non-specific 
(hydrotherapeutic  in  a  broad  sense)  mechanisms 
of simple bathing in hot tap water, and the specific 
(hydromineral  and  crenotherapeutic)  mechanisms, 
which depend on the chemical and physical proper-
ties of the water used. Whereas the former are well 
known, the latter are difficult to identify and assess. 
Buoyancy, immersion, resistance, and temperature all 
play important roles. Hot stimuli produces analgesia 
on nerve endings by increasing the pain threshold. It 
causes relief of muscle spasms through the gamma 
fibers of muscle spindles and activates the descend-
ing pain inhibitory system. According to the “gate 
  theory”, pain relief may be due to the temperature and 
hydrostatic pressure of water on the skin.30
Spa  therapy  provokes  a  series  of  endocrine 
  reactions, particularly in the release of adrenocorti-
cotropic  hormone  (ACTH),  cortisol,  prolactin  and 
growth hormone (GH), although it does not alter the 
circadian  rhythm  of  these  hormones.31 A  dysregu-
lation of the HPA axis, marked by mild hypocorti-
solemia and glucocorticoid feedback resistance, has 
been demonstrated in FS patients.32,33 These findings 
can explain the beneficial clinical effects of spa ther-
apy in FS.
Furthermore,  various  spa  therapy  techniques 
have been demonstrated to increase plasma levels of 
beta-endorphin.34,35  Interestingly,  it  has  been  found 
that application of mature thermal mud in healthy 
individuals brings about a rapid increase in plasma 
beta-endorphin, which returns to pretreatment levels 
within the period of the so-called thermal reaction.36 
This increase in beta-endorphin explains the analge-
sic and anti-spastic effect of spa therapy, which is par-
ticularly important in patients with FS and is one of 
the key factors in the mechanism of individual toler-
ance to thermal mud baths.Guidelli et al
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A recent study has shown a reduction in circulating 
levels of IL-1, PGE2 and LTB4, important mediators 
of inflammation and pain, in FS patients undergoing 
a cycle of balneotherapy.27 It has been suggested that 
inflammatory  process  mediated  by  cytokines,  pro-
teases, and inflammatory mediators located in the soft 
body tissue may play a role in the pathogenesis of FS, 
in up to one third of FS patients.37 This inflammatory 
process  would  stimulate  subcutaneous  nociceptors, 
resulting in a sensation of pain. The detection of IL-1, 
IL-6, and tumor necrosis factor-α (TNF-α) in the skin 
of one-third of FS patients, and elevated plasma PGE2 
levels  in  FS  support  this  hypothesis.38  In  another 
study of the same authors, it was demonstrated that 
reduction in masseter PGE2 level after intramuscular 
glucocorticoid administration was associated with a 
decrease in resting pain.39 The inhibitory effect of bal-
neotherapy on the production and/or release of IL-1, 
PGE2 and LTB4 could explain the mechanism of clini-
cal benefits of spa therapy in this disorder.   Mineral 
water  also  may  influence  the  oxidant-antioxidant 
system,  which  could  be  beneficial,  because  oxida-
tive stress disorders have been described in FS.40,41 In 
fact, in patients with FS, Bagis et al42 demonstrated 
an increase of serum malondialdehyde (MAD) and 
a  decrease  of  serum  superoxide  dismutase  (SOD), 
which support the hypothesis that FS is related to an 
imbalance of oxidant/antioxidant system.
Finally,  other  factors  may  contribute  positively 
to the beneficial effects of spa therapy in FS, such 
as  change  of  environment,  the  “spa-scenery”,  the 
absence of (house) work duties, physical and mental 
relaxation, the non-competitive atmosphere with sim-
ilarly suffering companions, and physical therapy.18–20 
As such, spa benefits could perhaps be attributed also 
to the effects of factors unrelated to the “water” ther-
apy per se. These spa benefits are especially impor-
tant in studies evaluating the effects of balneotherapy 
compared with no treatment or another treatment.
Discussion
The aim of this review was to summarize the currently 
available information on clinical effects and mecha-
nism of action of spa therapy in the management of 
FS. We  also  provide  some  suggestions  for  further 
development in this area. The results of the RCTs on 
spa therapy for FS suggest a positive effect on pain, 
other FS-related symptoms, and QoL.2,43 The studies 
assessed the medium-to-long-term effect and found 
that  the  clinical  efficacy  of  spa  therapy  lasted  for 
4–6 months. Despite low tolerance of physical treat-
ments by FS patients, spa therapy seems to be well 
tolerated and have a lower percentage of side effects, 
which also are less severe, than those associated with 
pharmacological treatments.
Some aspects of the studies on spa therapy for 
FS are disputable and could be a source of bias, for 
example, the lack of double-blind experimental design 
because of the difficulty of creating a placebo with 
the same characteristics as the treatment. Because of 
the lack of double-blinded studies, the placebo effect 
cannot be excluded and may contribute to confound 
results. The methodological quality of the RCTs ana-
lyzed was limited for the following reasons: (1) only 
two studies had a sample size of at least 25 per group, 
the number recognized as appropriate for detecting 
clinically significant differences between two active 
treatments;44  (2)  no  studies  distinguished  between 
different FS subgroups, such as patients with predom-
inant pain symptoms or patients with psychological 
involvement;45 (3) no study included intention-to-treat 
analysis, but analyzed the completers, possibly favor-
ing the results of spa therapy, even if the dropout rates 
were low; (4) most studies did not report the method 
of randomization used; and (5) the trials did not ensure 
that treatment allocation was concealed.2,43
Comparison  of  the  studies  was  difficult  as  the 
baseline characteristics of the patients were hetero-
geneous, the interventions differed in type, intensity, 
and  duration:  the  methods  used  for  assessment  of 
efficacy varied, and the patients were assessed at dif-
ferent times after the spa therapy. In particular, the 
heterogeneity of “spa therapy” makes it difficult to 
determine which form of spa therapy is most effec-
tive, and no study was designed to compare different 
types of spa care procedures.
Although the consistency of the results suggests 
that spa therapy has a therapeutic effect on FS, the 
methodological  limitations  of  the  studies  preclude 
any definitive conclusions.
Furthermore,  the  mechanisms  of  action  of  spa 
  therapy are not fully understood and one of the critical 
points is the controversial problem of the   absorption 
of the minerals dissolved in thermal waters that is 
the demonstration of specific effects other than those 
linked to the simple action of heat.Spa therapy and fibromyalgia
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conclusions
In conclusion, spa therapy seems to be effective and 
useful in FS, reducing pain, improving function, and 
ameliorating  QoL.  The  improvement  reported  in 
some clinical studies lasts over time.   Nevertheless, 
the methodological limitations of available clinical 
studies, such as the lack of placebo double-blinded 
trials,  preclude  definitive  conclusions.  It  cannot 
substitute conventional therapy but can complement 
to it. Actually, spa therapy can represent a useful 
backup  to  pharmacologic  treatment  of  FS  or  a 
valid alternative for patients who do not tolerate 
pharmacologic  treatments.  Future  studies  to 
clarify  the  mechanisms  of  action  and  the  effects 
derived from the application of thermal treatments, 
are  imperative.  Studies  conducted  according  to 
rigorous methodological criteria in larger numbers 
of patients are needed to determine the potential of 
spa therapy for FS.
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